The estimated Net Worth of Boris Nikolic is at least $132 Tysiąc dollars as of 2 June 2017. Boris Nikolic owns over 35,000 units of Editas Medicine Inc stock worth over $132,300 and over the last 9 years Boris sold EDIT stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Boris Nikolic EDIT stock SEC Form 4 insiders trading
Boris has made over 1 trades of the Editas Medicine Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Boris bought 35,000 units of EDIT stock worth $492,450 on 2 June 2017.
The largest trade Boris's ever made was buying 35,000 units of Editas Medicine Inc stock on 2 June 2017 worth over $492,450. On average, Boris trades about 8,750 units every 0 days since 2016. As of 2 June 2017 Boris still owns at least 35,000 units of Editas Medicine Inc stock.
You can see the complete history of Boris Nikolic stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Boris Nikolic's mailing address?
Boris's mailing address filed with the SEC is 11 Hurley St, Cambridge, MA 02141, USA.
Insiders trading at Editas Medicine Inc
Over the last 9 years, insiders at Editas Medicine Inc have traded over $73,429,036 worth of Editas Medicine Inc stock and bought 241,700 units worth $4,697,822 . The most active insiders traders include Andrew A. F. Hack, Kevin P Starr oraz Kevin Bitterman. On average, Editas Medicine Inc executives and independent directors trade stock every 22 days with the average trade being worth of $126,770. The most recent stock trade was executed by Baisong Mei on 4 September 2024, trading 518 units of EDIT stock currently worth $1,772.
What does Editas Medicine Inc do?
unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.
What does Editas Medicine Inc's logo look like?
Complete history of Boris Nikolic stock trades at Editas Medicine Inc
Editas Medicine Inc executives and stock owners
Editas Medicine Inc executives and other stock owners filed with the SEC include:
-
Cynthia Collins,
President, Chief Executive Officer, Director -
Charles Albright,
Executive Vice President, Chief Scientific Officer -
Dr. Bruce E. Eaton Ph.D.,
Exec. VP & Chief Bus. Officer -
Michelle Robertson,
CFO, Principal Accounting Officer, Treasurer & Assistant Sec. -
David Scadden,
Independent Director -
James Mullen,
Independent Chairman of the Board -
Jessica Hopfield,
Independent Director -
Andrew Hirsch,
Independent Director -
Dr. Lisa A. Michaels M.D.,
Exec. VP & Chief Medical Officer -
Akshay Vaishnaw,
Independent Director -
James C. Mullen,
Chairman, Pres & CEO -
Lisa Michaels,
Executive Vice President, Chief Medical Officer -
Mark Mullikin,
Investor Relations Officer -
Gad Berdugo,
Chief Business Officer -
Harry Gill,
Senior Vice President - Operations -
Michelle Robertson,
Chief Financial Officer -
Dr. Gilmore O'Neill,
Pres & CEO -
Charlene Stern J.D., Ph.D.,
Exec. VP & Gen. Counsel -
Ron Moldaver,
Investor Relations -
Dr. J. Keith Joung M.D., Ph.D.,
Co-Founder & Scientific Advisory Board Member -
Dr. George McDonald Church Ph.D.,
Co-Founder & Scientific Advisory Board Member -
Charlene Stern,
Sr. VP & Chief Legal Officer -
Dr. Mark S. Shearman,
Exec. VP & Chief Scientific Officer -
Harry R. Gill III,
Sr. VP of Operations -
Dr. David R. Liu,
Co-Founder & Scientific Advisory Board Member -
Dr. J. Keith Joung,
Co-Founder & Scientific Advisory Board Member -
Dr. George M. Church,
Co-Founder & Scientific Advisory Board Member -
Dr. Feng Zhang,
Co-Founder & Scientific Advisory Board Member -
Douglas G. Cole,
Director -
Katrine Bosley,
President and CEO -
Kevin P Starr,
10% owner -
Alexis Borisy,
Director -
Alexandra Glucksmann,
Chief Operating Officer -
Venture Management Co. Vi, ...,
-
Ventures Fund Iv, L.P.Flags...,
-
Kevin Bitterman,
Director -
Gerald Frank Cox,
Chief Medical Officer -
Ventures Fund Iv, L.P.Flags...,
-
John Mendlein,
Director -
Boris Nikolic,
Director -
Andrew A. F. Hack,
Chief Financial Officer -
Rock Ventures Iii, L.P.Thir...,
-
Llc Bng0,,
10% owner -
Bernadette Connaughton,
Director -
Elliott M. Levy,
Director -
Vickesh Myer,
Chief Technology Officer -
Global Investors Lp Viking ...,
-
Global Performance Llc Viki...,
-
James E Deerfield Mgmt Iii,...,
-
Baisong Mei,
EVP, CHIEF MEDICAL OFFICER -
Mark S Shearman,
EVP, CHIEF SCIENTIFIC OFFICER -
Meeta Chatterjee,
Director -
Bruce Eaton,
EVP, CBO AND CTO -
Emma Reeve,
Director -
Erick Lucera,
EVP, CHIEF FINANCIAL OFFICER -
Gilmore Neil O'neill,
CEO -
Linda Burkly,
EVP, CHIEF SCIENTIFIC OFFICER